IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 401–500 of 1,000
Orchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells
Penny, H. A., Hodge, S. H., & Hepworth, M. R. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0687-8 · Cited by 51
“and has been linked to an adverse prognosis and more aggressive disease [109], while mice deficient for IL-23 are resistant”
BackgroundResolvin E3 attenuates allergic airway inflammation via the interleukin‐23‐interleukin‐17A pathway
Sato, M., Aoki‐Saito, H., Fukuda, H., Ikeda, H., Koga, Y., Yatomi, M., Tsurumaki, H., Maeno, T., Saito, T., Nakakura, T., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900283r · Cited by 52
Functions of Dendritic Cells and Its Association with Intestinal Diseases
Yang, Z., Wang, B., Wang, T., Wang, F., Guo, Y., Hua, R., Shang, H., Lü, X., & Xu, J. (2021) · Cells · doi:10.3390/cells10030583 · Cited by 51
Grupp, S. A., & June, C. H. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_94 · Cited by 50
“It should be noted that IL-17 and IL-23 can promote tumor growth through tissue remodeling and other mechanisms (Langowski et al. 2006; Lin and Karin 2007), and that the potential use of Th17 cells for ACT is distinct from their potential roles in the pathogenesis of inflammation leading to cancer.”
BackgroundIL-23 in Infections, Inflammation, Autoimmunity and Cancer: Possible Role in HIV-1 and AIDS
Yannam, G. R., Gutti, T. L., & Poluektova, L. Y. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9315-2 · Cited by 54
“tissues, thus protecting against chemically induced carcinogenesis (Langowski et al. 2006).”
BackgroundInfluentialLu, Y.-P., Chen, X., Liu, X., Shi, Y. P., Wei, Z., Feng, L., Jiang, Q., Ye, W., Sasaki, T., Fukunaga, K., et al. (2023) · Autophagy · doi:10.1080/15548627.2022.2162244 · Cited by 47
Breathing new insights into the role of mutant p53 in lung cancer
Chen, T., Ashwood, L. M., Kondrashova, O., Strasser, A., Kelly, G., & Sutherland, K. D. (2025) · Oncogene · doi:10.1038/s41388-024-03219-6 · Cited by 46
Self-citationAutoimmunity as a Double Agent in Tumor Killing and Cancer Promotion
Toomer, K. H., & Chen, Z. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00116 · Cited by 47
“comprehensive examination of gene expression profiles in human cancers revealed overexpression of IL-23 in the vast majority of human carcinomas, when compared to expression profiles of adjacent, non-cancerous tissue (130).”
BackgroundUstekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
Deepak, P., & Loftus, E. V. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s102141 · Cited by 47
“The data for the risk of cancers in murine studies are conflicting because of the antitumor activity of IL-12 contrasting with the tumor promotion effect of IL-23.”
Kang, Y., Su, G., Sun, J., & Zhang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8586 · Cited by 54
“I L - 23 of inflammation that contribute to carcinogenesis (29,30).”
Foxo transcription factors in T cell biology and tumor immunity
Luo, C. T., & Li, M. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.006 · Cited by 46
Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells
Hemdan, N. Y. A. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.11.002 · Cited by 49
“Whereas enhanced Th17 response and related molecules such as interleukin (IL)-17, IL-21, IL-22, IL-23 and STAT3 accompanied tumor induction and progression, finding that tumor growth/stage was negatively correlated with increased infiltration of Th17 cells in the tumor mass has prompted elucidation of various antitumo…”
InfluentialZaķe, T., Skuja, S., Kalere, I., Konrāde, I., & Groma, V. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0396 · Cited by 46
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis
Gisondi, P., Geat, D., Pizzolato, M., & Girolomoni, G. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.05.007 · Cited by 46
M’Koma, A. E., Moses, H. L., & Adunyah, S. E. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1137-4 · Cited by 48
“IL-23 is upregulated in some human tumors, whereas its deletion leads to increased infiltration of cytotoxic T cells and growth restriction of transformed or transplanted tumors [117].”
BackgroundA novel immunoregulatory function for IL‐23: Inhibition of IL‐12‐dependent IFN‐γ production
Sieve, A. N., Meeks, K. D., Lee, S., & Berg, R. E. (2010) · European Journal of Immunology · doi:10.1002/eji.200939759 · Cited by 47
RETRACTED: Immunosuppressive networks in the tumour environment and their effect in dendritic cells
Bennaceur, K., Chapman, J. A., Touraine, J. L., & Portoukalian, J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.001 · Cited by 55
“Expression of the heterodimeric cytokine interleukin (IL)-23, is increased in human tumours [90,91] and regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes [92].”
BackgroundRetractedCellular Mediators of Inflammation: Tregs and TH17 Cells in Gastrointestinal Diseases
Pandolfi, F., Cianci, R., Pagliari, D., Landolfi, R., & Cammarota, G. (2009) · Mediators of Inflammation · doi:10.1155/2009/132028 · Cited by 51
“TH17 may also contribute to tumor progression due to the role of their cytokines in inflammation and tissue repair [67].”
BackgroundLan, F., Zhang, L., Wu, J., Zhang, J., Zhang, S., Li, K., Qi, Y., & Lin, P. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1232-6 · Cited by 47
“As a result, IL-23 may rely on the Th17/IL-17 pathway to play a vital role in malignant transformation.”
BackgroundInfluentialIL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma
Suzuki, H., Ogawa, H., Miura, K., Haneda, S., Watanabe, K., Ohnuma, S., Sasaki, H., Sase, T., Kimura, S., Kajiwara, T., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.739 · Cited by 44
“In a cutaneous carcinogenesis model, IL-23a knockout rodents demonstrated decreased skin tumor formation (11).”
Mouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer
Kim, B. S., Kuen, D., Koh, C., Kim, H., Chang, S. H., Kim, S., Jeon, Y. K., Park, Y.-J., Choi, G., Kim, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002603 · Cited by 49
Mocellin, S., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20110 · Cited by 47
Inciting inflammation: the RAGE about tumor promotion
Dougan, M. L., & Dranoff, G. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080136 · Cited by 44
Regulatory T Cells and Cancer: A Two-Sided Story
Wang, K., & Vella, A. T. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1197242 · Cited by 46
“induction, these mice developed few skin tumors, similar to that of IL-23 knockout (Langowski et al., 2006).”
BackgroundInfluentialLo, J. W., Cozzetto, D., Alexander, J. L., Danckert, N. P., Madgwick, M., Knox, N., Sieh, J. Y. X., Olbei, M. L., Liu, Z., Ibraheim, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41798-2 · Cited by 49
“Unlike with blockade of IFN γ , which would impact the anti-tumour immunity 47 , IL23 blockade is unlikely to impede systemic, anti-cancer immunity, and neutralisation of the IL23 might even promote favour-ablecanceroutcomes 48 – 50 .”
BackgroundEnhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells
Foerster, F., Boegel, S., Heck, R., Pickert, G., Rüssel, N., Rosigkeit, S., Bros, M., Strobl, S., Kaps, L., Aslam, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1409929 · Cited by 48
Guselkumab for the treatment of psoriasis
Megna, M., Balato, A., Raimondo, A., & Balato, N. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1445223 · Cited by 43
“Moreover, the indirect comparison with other biologics approved for psoriasis treatment shows a tendency to a higher PASI 75, PASI 90, and PASI 100 responses for guselkumab with respect to anti-TNF-α (adalimumab, etanercept, and inflixmab), one anti-IL-17 (secukinumab) and anti-IL-12/23 (ustekinumab), whereas almost c…”
BackgroundInfluentialThe phosphatidic acid phosphatase lipin-1 facilitates inflammation-driven colon carcinogenesis
Meana, C., García‐Rostán, G., Peña, L., Lordén, G., Cubero, Á., Orduña, A., Győrffy, B., Balsinde, J., & Balboa, M. A. (2018) · JCI Insight · doi:10.1172/jci.insight.97506 · Cited by 45
“Mediators such as IL-23 activate mitogenic pathways that trigger the expansion of premalignant clones (5).”
BackgroundKridin, K., Abdelghaffar, M., Mruwat, N., Ludwig, R. J., & Thaçi, D. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19520 · Cited by 42
“29,30 In mice bearing dormant tumours induced by MCA, inhibition of IL-23 resulted in the elimination of the residual tumour cells.”
BackgroundJiao, J., Zhao, X., Liang, Y., Tang, D., & Pan, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.021 · Cited by 42
Overexpression of type VI collagen in neoplastic lung tissues
Voiles, L., Lewis, D. E., Han, L., Lupov, I. P., Lin, T., Robertson, M. J., Petrache, I., & Chang, H. (2014) · Oncology Reports · doi:10.3892/or.2014.3438 · Cited by 42
“IL-23 has been implicated in the development of cancers (34).”
BackgroundResultInfluentialvon Scheidt, B., Leung, P. S. K., Yong, M. C. R., Zhang, Y., Towne, J. E., Smyth, M. J., & Teng, M. W. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1646 · Cited by 41
“tumor initiation, growth, and metastases, and that IL-23 can inhibit natural killer (NK) cell effector functions (3, 4).”
BackgroundClinical significance of circulating interleukin‐23 as a prognostic factor in breast cancer patients
Gangemi, S., Minciullo, P. L., Adamo, B., Franchina, T., Ricciardi, G. R. R., Ferraro, M., Briguglio, R., Toscano, G., Saitta, S., & Adamo, V. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24083 · Cited by 42
“It has a pro-carcinogenic activity, promoting inflammation and angiogenesis within the tumor microenvironment while reducing CD8þ T cell infiltration [Langowski et al., 2006].”
BackgroundHuckans, M. S., Fuller, B. E., Olavarria, H., Sasaki, A. W., Chang, M., Flora, K. D., Kolessar, M., Kříž, D., Anderson, J. R., Vandenbark, A. A., et al. (2013) · Brain and Behavior · doi:10.1002/brb3.200 · Cited by 49
“Brain and Behavior published by Wiley Periodicals, Inc. subsets that produce IL-17, a proinflammatory cytokine that can stimulate the production of other proinflammatory factors, such as IL-1, IL-6, and TNF-a; Kikly et al. 2006; Langowski et al. 2006).”
BackgroundImmune modulation by ER stress and inflammation in the tumor microenvironment
Rodvold, J. J., Mahadevan, N. R., & Zanetti, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.009 · Cited by 44
Li, X., Lü, P., Li, B., Zhang, W., Yang, R., Chu, Y., & Luo, K. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.03.003 · Cited by 43
“Bars (Langowski et al., 2006).”
BackgroundIL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity
Fukuda (2010) · International Journal of Oncology · doi:10.3892/ijo_00000620 · Cited by 44
Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring
Maryam, S., Krukiewicz, K., Haq, I. U., Khan, A. A., Yahya, G., & Cavalu, S. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093127 · Cited by 42
Innate Lymphoid Cells in Tumor Immunity
van Beek, J. J. P., Martens, A. W. J., Bakdash, G., & de Vries, I. J. M. (2016) · Biomedicines · doi:10.3390/biomedicines4010007 · Cited by 42
“Human colon tumors have elevated levels of IL-23 compared to healthy tissue [84].”
Interleukin-23 as a therapeutic target for inflammatory myopathy
Umezawa, N., Kawahata, K., Mizoguchi, F., Kimura, N., Yoshihashi‐Nakazato, Y., Miyasaka, N., & Kohsaka, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-23539-4 · Cited by 41
Intrahepatic TH17/TReg Cells in Homeostasis and Disease—It’s All About the Balance
Drescher, H. K., Bartsch, L. M., Weiskirchen, S., & Weiskirchen, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588436 · Cited by 47
Interleukin-22: a sheep in wolf's clothing
Laurence, A. D. J., O’Shea, J. J., & Watford, W. T. (2008) · Nature Medicine · doi:10.1038/nm0308-247 · Cited by 40
Stat3: Linking inflammation to (gastrointestinal) tumourigenesis
Ernst, M., & Putoczki, T. L. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05659.x · Cited by 44
“the angiogenic factors vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-a in fibroblasts and endothelial cells, IL-17 and IL-23 promote tumourigenesis.(33,34) It has been shown that Stat3 is indispensible for the development and reinforcement of the Th17 phenotype because it mediates the…”
BackgroundThe IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Joerger, M., Finn, S. P., Cuffe, S. D., Byrne, A. T., & Gray, S. G. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1206891 · Cited by 42
Chen, D., Li, W., Liu, S., Su, Y., Han, G., Xu, C., Liu, H., Zheng, T., Zhou, Y., & Mao, C. (2015) · Scientific Reports · doi:10.1038/srep08604 · Cited by 45
Wakita, D., Chamoto, K., Ohkuri, T., Narita, Y., Ashino, S., Sumida, K., Nishikawa, H., Shiku, H., Togashi, Y., Kitamura, H., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp144 · Cited by 39
Th17 and cancer: friends or foes?
Bronte, V. (2008) · Blood · doi:10.1182/blood-2008-04-149260 · Cited by 39
Interleukin-17 and type 17 helper T cells in cancer management and research
Housseau, F., Geis, A. L., Orberg, E. T., & Llosa, N. J. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s56529 · Cited by 43
“While IL-23 deficient mice have been shown to be resistant to carcinogen-induced skin cancer, IL-23-transduced DCbased vaccine can lead to strong antitumor responses with increased CD8+ cytotoxic T cell recruitment.(87,88) A Phase II clinical trial of therapies targeting IL-12/p40, common to IL-12 and IL-23, showed en…”
BackgroundYue, T., Zheng, X., Dou, Y., Zheng, X., Sun, R., Tian, Z., & Wei, H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2701-7 · Cited by 40
“Accordingly, the growth of B16 melanomas is faster in mice that are deficient in the IL-12 receptor chain IL-12Rβ2 compared to WT mice [14, 15].”
BackgroundLim, K., Yong, Z. W. E., Wang, H., Tan, T. Z., Huang, R. Y., Yamamoto, D., Inaki, N., Hazawa, M., Wong, R. W.-C., Oshima, H., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012943 · Cited by 39
“Although the link between IL-23 and carcinogenesis is well established, its tumorigenic activity is generally considered an adverse consequence of its perpetuation of chronic inflammation (12,13).”
BackgroundInfluentialInterleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy
Zhou, Y., Yoshida, S., Kubo, Y., Kobayashi, Y., Nakama, T., Yamaguchi, M., Ishikawa, K., Nakao, S., Ikeda, Y., Ishibashi, T., et al. (2016) · Scientific Reports · doi:10.1038/srep28140 · Cited by 40
High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer
Carvalho, D. F. G., Zanetti, B. R., Miranda, L., Hassumi, M. K., Miranda-Camargo, F. A., Crispim, J. C. D. O., & Soares, E. G. (2017) · Oncology Letters · doi:10.3892/ol.2017.5638 · Cited by 41
Pellegrini, C., Orlandi, A., Costanza, G., Stefani, A. D., Piccioni, A., Cesare, A. D., Chiricozzi, A., Ferlosio, A., Peris, K., & Fargnoli, M. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183415 · Cited by 41
The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas
Qiu, L., He, D., Fan, X., Li, Z., Liao, C., Zhu, Y., & Wang, H. (2011) · Pituitary · doi:10.1007/s11102-011-0292-5 · Cited by 38
“IL-17 was also found to be expressed at high levels in the hyperplastic skin in the DMBA/TPA model and were consistent with that increased levels of local IL-6, TGFh, and TNFa in papilloma development [ 44 , 45], these results strongly suggest a role for IL-17 family members in amplifying and sustaining chronic inflam…”
ResultTargeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 42
Okuyama, H., Tominaga, A., Fukuoka, S., Taguchi, T., Kusumoto, Y., & Ono, S. (2017) · Oncology Reports · doi:10.3892/or.2017.5346 · Cited by 37
“Recent studies have revealed that IL-23/IL-17 signaling plays an important role in tumorigenesis and metastasis in humans and in mice (11-16).”
BackgroundFunction of innate lymphoid cells in the immune-related disorders
Džopalić, T., Nedeljković, B. B., & Jurišić, V. (2019) · Human Cell · doi:10.1007/s13577-019-00257-1 · Cited by 38
Kawanishi, Y., Tominaga, A., Okuyama, H., Fukuoka, S., Taguchi, T., Kusumoto, Y., Yawata, T., Fujimoto, Y., Ono, S., & Shimizu, K. (2013) · Microbiology and Immunology · doi:10.1111/1348-0421.12001 · Cited by 36
“By contrast, IL-23, a Th17 maturation and maintenance factor, reportedly promotes tumor growth (23).”
BackgroundShi, G., & Hu, Y. (2023) · Cancers · doi:10.3390/cancers15174299 · Cited by 38
“CSF1 and CCL22 recruited macrophages and IL-23A blocked CD8 T-cell infiltration [49].”
BackgroundAssociation of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer
Zhang, Z., Zhou, B., Zhang, J., Chen, Y., Lai, T., Li, Y., Liang, A., Li, Y., Wang, Y., Chen, Y., et al. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.09.006 · Cited by 36
“These mice are almost completely resistant to endogenous tumor formation when challenged in a chemical carcinogenesis protocol [15].”
BackgroundCurrent investigational drugs in psoriasis
Ryan, C., Abramson, A. K., Patel, M., & Menter, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.669372 · Cited by 36
“IL-23, in contrast, appears to promote tumor growth, suggesting that inhibition of this cytokine may inhibit carcinogenesis [49].”
BackgroundRole of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications
Kumar, J., & Ward, A. C. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.003 · Cited by 45
The Yin and Yang of Innate Lymphoid Cells in Cancer
Carrega, P., Campana, S., Bonaccorsi, I., & Ferlazzo, G. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.06.003 · Cited by 38
“Although IL-23 has traditionally been studied for their roles in host defense, auto-immunity and chronic inflammatory diseases, elevated expression of this cytokines and its receptor has also been detected in various human cancers, including those of the colon, ovaries, lung, breast, stomach, skin, liver, and head and…”
BackgroundAccelerated wound healing phenotype in Interleukin 12/23 deficient mice
Matias, M. A. T. J., Saunus, J. M., Ivanovski, S., Walsh, L. J., & Farah, C. S. (2011) · Journal of Inflammation · doi:10.1186/1476-9255-8-39 · Cited by 41
“Blockade of IL-12/IL-23p40 through its effects on IL-23 may also influence wound healing by up-regulation of MMP-9 which has downstream effects on angiogenesis [22].”
BackgroundRausch, M. P., & Sertil, A. R. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1018415 · Cited by 41
“[101] Langowski JL, Zhang X, Wu L, et al.”
BackgroundMikkelsen, K., Dargahi, N., Fraser, S., & Apostolopoulos, V. (2023) · Biomedicines · doi:10.3390/biomedicines11092578 · Cited by 40
“IL-23-a expression is substantially increased in several human cancers [70], leading to its tumour-promoting properties.”
BackgroundAssociations of IL-23 with Polypoidal Choroidal Vasculopathy
Sasaki, S.-I., Miyazaki, D., Miyake, K.-I., Terasaka, Y., Kaneda, S., Ikeda, Y., Funakoshi, T., Baba, T., Yamasaki, A., & Inoue, Y. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7913 · Cited by 36
Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance
Sheng, S., Zhang, J., Ai, J., Hao, X., & Luan, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8427 · Cited by 40
Allegra, A., Musolino, C., Tonacci, A., Pioggia, G., Casciaro, M., & Gangemi, S. (2020) · Cancers · doi:10.3390/cancers12020524 · Cited by 39
IL-12 and Related Cytokines: Function and Regulatory Implications in Candida albicans Infection
Ashman, R. B., Vijayan, D., & Wells, C. A. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/686597 · Cited by 35
“It also increases local activity of the matrix metalloproteinase, MMP-9, increases angiogenesis, and reduces CD8+ T-cell infiltration [9].”
BackgroundChu, H., Cao, W.-K., Chen, W., Pan, S., Xiao, Y., Liu, Y., Gu, H., Guo, W., Xu, L., Hu, Z., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26130 · Cited by 36
“IL-23/IL-23R is specifically essential for Th17 cell-mediated immune response(4,5) and links tumor-promoting proinflammatory processes and the failure of the adaptive immune surveillance.(6) Several studies reported that IL-12 single nucleotide polymorphisms (SNPs) were associated with cancers.”
BackgroundXu, Y., Liu, Y., Pan, S., Liu, L., Liu, J., Zhai, X., Shen, H., & Hu, Z. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0620-1 · Cited by 35
LDHA: The Obstacle to T cell responses against tumor
Tang, Y., Gu, S., Zhu, L., Wu, Y., Zhang, W., & Zhao, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1036477 · Cited by 39
“The research revealed that lactic acid impeded the infiltration of CD8 T cells by promoting the interleukin (IL)-23 expression and secretion (81, 82).”
BackgroundAdvances in molecular mechanisms of inflammatory bowel disease‑associated colorectal cancer (Review)
Wang, Z., Chang, Y., Sun, H., Li, Y., & Tang, T. (2024) · Oncology Letters · doi:10.3892/ol.2024.14390 · Cited by 37
“In addition, the IL‑23 / Th‑17 axis can also promote exces‑ sive proliferation of IBD‑CRC through mechanisms such as increased angiogenesis, upregulation of MMP‑9 and reduced infiltration of CD8+ T cells, thus improving its tumourigenic capacity (66).”
BackgroundInterleukin‐23 receptor polymorphism as a risk factor for oral cancer susceptibility
Chien, M., Hsin, C., Chou, L. S., Chung, T., Lin, C., Weng, M., Chou, M., Chen, M., & Yang, S. (2011) · Head & Neck · doi:10.1002/hed.21779 · Cited by 34
“First, the dominance of IL-23-mediated pathways in early chemical carcinogenesis suggests a role in evading detection or elimination of CD8þ T cells.(21) Second, IL-23 promotes tissue restructuring through matrix metallopro-”
BackgroundResultInfluentialIncreased expression of interleukin‐23 associated with progression of colorectal cancer
Hu, W., Chen, H., Yen, S., Huang, H., Hsiao, C., & Chuang, J. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24505 · Cited by 35
“IL-23p19 messenger RNA (mRNA) expression is significantly increased in human colorectal cancer tissue compared with that in adjacent normal tissue [13,14].”
BackgroundGroup 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?!
Pantazi, E. D., & Powell, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00676 · Cited by 40
“Recent studies describe their involvement in several immune-mediated diseases such as psoriasis (34, 35), multiple sclerosis (36), or cancer (37, 38), improving our understanding of these highly plastic cells in controlling inflammation, while suggesting new ways of therapeutic immune intervention.”
BackgroundThe Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
McCuaig, S., Barras, D., Mann, E. H., Friedrich, M., Bullers, S. J., Janney, A., Garner, L. C., Domingo, E., Koelzer, V. H., Delorenzi, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1086 · Cited by 42
Tristetraprolin Down-Regulates IL-23 Expression in Colon Cancer Cells
Lee, H. H., Yang, S. S., Vo, M., Cho, W. J., Lee, B. J., Leem, S., Lee, S., Cha, H. J., & Park, J. W. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0268-6 · Cited by 34
“In a recent study, IL-23 emerged as a new player in the promotion of tumor growth and development through suppression of tumor infiltration of CD8+ T cells and promotion of tumor angiogenesis and metastases (Langowski et al., 2006; Teng et al., 2010).”
BackgroundInfluentialPappu, B. P., Angkasekwinai, P., & Dong, C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.003 · Cited by 38
“IL-17 has long been implicated in several autoimmune diseases, primarily as a proinflammatory regulator (Tartour et al., 1999; Witowski et al., 2004; Langowski et al., 2006).”
BackgroundMiteva, L. D., Stanilov, N., Deliysky, T. S., Mintchev, N., & Stanilova, S. A. (2009) · Cancer Investigation · doi:10.3109/07357900902918486 · Cited by 34
“(27) have reported that IL-23 promotes tumor incidence and growth.”
BackgroundFaucheux, L., Grandclaudon, M., Perrot-Dockès, M., Sirven, P., Berger, F., Hamy, A., Fourchotte, V., Vincent‐Salomon, A., Mechta‐Grigoriou, F., Reyal, F., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1624130 · Cited by 37
“In breast cancer, the role of Th17 differs across studies.(45,46) Higher Th17 infiltration was shown in TN breast cancer,(17,18), but its specific prognostic impact was not assessed within TN tumors (stratified as Th17 high or low) or across tumor types independently of its association with TN.”
BackgroundChien, A. L.-L., Elder, J. T., & Ellis, C. N. (2009) · Drugs · doi:10.2165/00003495-200969090-00001 · Cited by 34
“IL-23 inhibition may help immune cells infiltrate and attack tumours.([112]) Therefore, long-term clinical studies or registries are needed to explore the risk in humans.”
Th17 cells: a third subset of CD4+ T effector cells involved in organ-specific autoimmunity
Kurts, C. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm800 · Cited by 45
Hidalgo‐Garcia, L., Ruiz‐Malagón, A. J., Huertas, F., Rodríguez‐Sojo, M. J., Molina‐Tijeras, J. A., Diez‐Echave, P., Becerra, P., Mirón, B., Morón, R., Rodríguez‐Nogales, A., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106891 · Cited by 36
“In addition, the IL-23-inducible gene matrix metalloproteinase-9 ( Mmp-9 ), and angiopoietin-2 ( Angpt-2 ), both prognostic factors associated with poor survival in CRC [38,39], were reduced in CAC + iMSCs mice in comparison to CAC control mice (Fig.”
Preclinical development of AMG 139, a human antibody specifically targeting IL ‐23
Köck, K., Pan, W., Gow, J. M., Horner, M. J., Gibbs, J. P., Colbert, A., Goletz, T. J., Newhall, K. J., Rees, W. A., Sun, Y., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12904 · Cited by 36
“This is especially important because of the predominant role of IL-12 in defence against intracellular pathogens and tumour immune surveillance (Fieschi and Casanova, 2003; Bowman et al., 2006; Langowski et al., 2006; Meeran et al., 2006; Schulz et al., 2008) and the controversially debated safety concerns (increased…”
BackgroundMethodInfluentialStressed Out - Therapeutic Implications of ER Stress Related Cancer Research
Riha, R., Gupta-Saraf, P., Bhanja, P., Badkul, S., & Saha, S. (2017) · Oncomedicine · doi:10.7150/oncm.22477 · Cited by 34
“Two specific secreted cytokines, IL-6 and IL-23, have been implicated in tumor growth [83, 84].”
Chiba, Y., Mizoguchi, I., Furusawa, J.-I., Hasegawa, H., Ohashi, M., Xu, M., Owaki, T., & Yoshimoto, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0960 · Cited by 35
IL-23 and the Tumor Microenvironment
Subhadarshani, S., Yusuf, N., & Elmets, C. A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55617-4_6 · Cited by 38
Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms
Ru, Y., Ding, X., Luo, Y., Li, H., Sun, X., Zhou, M., Zhou, Y., Kuai, L., Xing, M., Liu, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670398 · Cited by 37
“2) than anti-IL-23-p19 treatment, which may be related to its structural features (65).”
BackgroundDoes IL-17 promote tumor growth?
Muranski, P. J., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-04-215541 · Cited by 35
Lo, C., Chang, C., Tang, S., Pan, W., Fang, C., Chen, Y., Wu, P., Chen, K., Ma, H., Xiao, X., et al. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1452 · Cited by 34
“However, later studies showed that IL-23 decreases the number and activity of cytotoxic T cells within the tumor environment [39], and also activates tumor-associated Foxp3+ regulatory T cells [43].”
BackgroundAnimal models for bladder cancer: The model establishment and evaluation (Review)
Zhang, N., Li, D., Shao, J., & WANG, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.2888 · Cited by 35
“Mice in which genes, such as interferon-γ and interleukin 17, 12 and 23, among others, are knocked out, are being used to determine how different components of the immune system either promote or inhibit the development of bladder tumors (42-44).”
Ma, H., Xu, J., Liu, X., Zhu, Y., Gao, B., Karin, M., Tsukamoto, H., Jeste, D. V., Grant, I., Roberts, A. J., et al. (2016) · Current Pathobiology Reports · doi:10.1007/s40139-016-0097-3 · Cited by 34
Pedrini, S., Gupta, V. B., Hone, E., Doecke, J. D., O’Bryant, S. E., JAMES, I. R., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14020-9 · Cited by 35
Ergen, E. N., & Yusuf, N. (2018) · Experimental Dermatology · doi:10.1111/exd.13676 · Cited by 34
An array of possibilities in cancer research using cytokine antibody arrays
Huang, R. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.2.299 · Cited by 33
Chen, B., Zeng, Z., Xu, L., Wu, X., Yu, J. Q., Xue, L., Hao, Y., Wang, Y., Sung, J. J. �., Chen, M., et al. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.08.006 · Cited by 32
Rodríguez, D., Silvera, R., Carrió, R., Nadji, M., Caso, R., Rodríguez, G., Iragavarapu‐Charyulu, V., & Torroella‐Kouri, M. (2013) · Cellular Immunology · doi:10.1016/j.cellimm.2013.06.008 · Cited by 36
“Given that the IL-12p40 chain is shared by the proinflammatory cytokines IL-12p70 and IL-23, we examined the expression of IL-23 protein (associated with tumor progression [23]) in the three macrophage subpopulations.”
Background
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.